Journal article
Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study
Abstract
In the setting of prior myocardial infarction, the oral antiplatelet ticagrelor added to aspirin reduced the risk of recurrent ischemic events, especially, in those with diabetes mellitus. Patients with stable coronary disease and diabetes are also at elevated risk and might benefit from dual antiplatelet therapy. The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS, NCT01991795) is a Phase 3b …
Authors
Bhatt DL; Fox K; Harrington RA; Leiter LA; Mehta SR; Simon T; Andersson M; Himmelmann A; Ridderstråle W; Held C
Journal
Clinical Cardiology, Vol. 42, No. 5, pp. 498–505
Publisher
Wiley
Publication Date
5 2019
DOI
10.1002/clc.23164
ISSN
0160-9289
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AgedAspirinClinical Trials, Phase III as TopicCoronary Artery DiseaseDiabetes Mellitus, Type 2Double-Blind MethodDrug Therapy, CombinationFemaleHumansHypoglycemic AgentsMaleMiddle AgedMyocardial InfarctionPlatelet Aggregation InhibitorsRandomized Controlled Trials as TopicRisk FactorsStrokeTicagrelorTime FactorsTreatment Outcome